Lymphoma & Plasma Cell Disorders
Conference Coverage
FDA panel leans toward more robust breast implant surveillance
SILVER SPRING, MD. – Amid concern over two breast implant complications – anaplastic large cell lymphoma and autoimmune symptoms – an FDA panel...
News
MCL survival rates improve with novel agents
Median overall survival for mantle cell patients was between 52 and 57 months in two cancer registries. The researchers pointed to the impact of...
News
Worse survival seen among black patients with MCL
There was a survival gap between black and white patients, even though black patients with mantle cell lymphoma were more likely to be treated in...
News
Oral triplet deemed effective in relapsed/refractory myeloma
Combination clarithromycin, pomalidomide, and dexamethasone may be a treatment option for patients with relapsed or refractory multiple myeloma....
News
Myeloma risk score has treatment-planning potential
The score could be used to modify doses prior to treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
Selinexor hits FDA stumbling block
The Oncologic Drugs Advisory Committee expressed concern about the high rate of serious adverse events with the drug being developed to treat...
News
Similar results for once- or twice-weekly carfilzomib in MM
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
News
Haplo-HCT shows viability in DLBCL
Survival rates were similar for matched and unmatched donors.
News
Researchers characterize new subtype of high-grade DLBCL
Patients with this subtype had distinct molecular features and poor prognosis.
